ENVIRONMENT/INFECTION/GENE INTERACTIONS IN AUTOIMMUNE DISEASE

Release Date:  February 4, 1999

RFA:  ES-99-003

P.T.

National Institute of Environmental Health Sciences
National Institute of Allergy and Infectious Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Arthritis, Musculoskeletal, and Skin Diseases
National Institute of Child Health and Human Development
National Institute on Deafness and other Communication Disorders
National Eye Institute
National Heart, Lung and Blood Institute
National Institute of Neurological Disorders and Stroke
National Institute of Mental Health
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health

Letter of Intent Receipt Date:  March 12, 1999
Application Receipt Date:  May 7, 1999

PURPOSE

The National Institute of Environmental Health Sciences (NIEHS), National
Institute of Allergy and Infectious Diseases (NIAID), National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of
Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), National Institute of
Child Health and Human Development (NICHD), National Institute on Deafness and
other Communication Disorders (NIDCD), National Eye Institute (NEI), National
Heart, Lung and Blood Institute (NHLBI), National Institute of Neurological
Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH),
National Institute of Dental and Craniofacial Research (NIDCR), and the Office
of Research on Women's Health (ORWH) invite applications for innovative
investigator-initiated basic or population based research to determine the role
of environmental and infectious agents in the initiation and/or exacerbation of
autoimmune diseases.  Three specific areas of interest are:  1) the role of
exposure to environmental and/or infectious agents in the development of
autoimmune diseases, including timing of exposure; 2) the role of genetic factors
in modulating the induction or perpetuation of autoimmune diseases by
environmental or infectious agents and 3) the interaction of hormones and gender
differences with environmental or infectious agents in development of autoimmune
diseases.  It is anticipated that research fostered by this RFA will lead to the
development of more extensive hypothesis-driven mechanistically-oriented research
projects.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led national
activity for setting priority areas.  This RFA, Environment/Infection/Gene
Interactions in Autoimmune Diseases, is related to one or more of the priority
areas.  Potential applicants may obtain a copy of "Healthy People 2000" at: 
http://www.crisny.org/health/us/health7.html.

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic, for-profit and non-profit
organizations, public and private, such as universities, colleges, hospitals,
laboratories, units of State and local governments, and eligible agencies of the
Federal government.  Foreign institutions may not submit applications in response
to this RFA.  Racial/ethnic minority individuals, women, and persons with
disabilities are encouraged to apply as Principal Investigators.

MECHANISM OF SUPPORT

This Request for Applications (RFA) will use the National Institutes of Health
(NIH) Exploratory Research Grant (R21) mechanism.  Specific R21 application
instructions have been modified to reflect 'MODULAR GRANT' and JUST IN TIME'
concepts.  The R21 grants provide support to develop new research activities in
categorical program areas.  These pilot/feasibility grants provide support for
high risk/high payoff activities that lack a traditional historical basis or
sufficient preliminary data.  Indeed areas of science in which there is a
sufficient historical base or sufficient preliminary data to support the
submission of a regular research project (R01) do not qualify under this RFA. 
Responsibility for the planning, direction, and execution of the proposed project
will be solely that of the applicant.  Applications in response to this RFA may
request from one to three years of support.  This RFA is a one-time solicitation. 
Future unsolicited competing continuation applications will compete with all
investigator-initiated applications and be reviewed according to the customary
peer review procedures.  The anticipated award date is September 1999.

For this RFA, funds must be requested in modules of $25,000 (direct cost), with
a minimum of two modules and no more than four modules requested in total.  A
feature of the modular grant concept is that no escalation is provided for future
years, and all anticipated expenses for all years of the project must be included
within the modules being requested.  Only limited budgetary information will be
required and any budget adjustments made by the initial review group will be in
modules of $25,000.  Instructions for completing the biographical sketch have
also been modified.  These modifications are described below in the application
procedure section.

FUNDS AVAILABLE

The estimated total funds (direct and indirect costs) available for the first
year of support for all awards made under this RFA will be $2.5M.  In Fiscal year
1999, the participating Institutes plan to fund approximately 15 to 18 new
grants.  An applicant may request a project period of one to three years and a
budget for direct costs of $50,000, $75,000, or $100,000 per year.  Although this
program is provided for in the financial plans of the IC(s), awards pursuant to
this RFA are contingent upon the receipt of a sufficient number of applications
of outstanding scientific and technical merit.

RESEARCH OBJECTIVES

Background

Approximately 80 separate autoimmune diseases, including Graves' disease,
Hasimoto's thyroiditis, rheumatoid arthritis, type 1 diabetes mellitus, multiple
sclerosis, systemic lupus erythematosus, inflammatory bowel disease, psoriasis,
uveitis, Sjogren's syndrome, autoimmune inner ear disease and scleroderma, affect
over 9 million Americans (1 in 31).  Autoimmune mechanisms may also underlie
rapidly progressive sensorineural hearing loss with or without vertigo and
certain childhood neuropsychiatric disorders such as obsessive compulsive
disorder and Tourette's disorder.  Women and some minorities are
disproportionately affected by many autoimmune disease.  All of these diseases
result from an attack of the immune system on the body's own tissues.

Environmental and infectious agents and/or their products have been implicated
in the pathogenesis of autoimmune diseases.  Several environmental chemicals have
been associated with autoimmune diseases, including silica dust and lupus, vinyl
chloride and organic solvents in scleroderma, mercury, gold or perchloroethylene
in autoimmune kidney disease, and polybrominated biphenyls in autoimmune thyroid
disease.  Environmental chemicals may also contribute to autoimmune liver disease
(e.g. non-alcoholic steatohepatitis or NASH). Infection with Campylobacter jejuni
is a common antecedent of the Guillain-Barre syndrome, an autoimmune neurologic
disease.  An association of rheumatoid arthritis with various organisms,
including mycoplasma, Epstein-Barr virus, parvovirus, and rubella, has been
suggested, but not convincingly proven.  Type 1 diabetes, a metabolic disease
caused by immune destruction of the pancreatic beta cells, has also been
associated epidemiologically with various infectious agents, including rubella,
rotovirus, and Coxsackie virus, although causality has not been established.  In
addition, various viral and bacterial peptides are able to activate myelin basic
protein specific T- cell clones, which were isolated from patients with multiple
sclerosis.

Interaction of the immune and endocrine systems is now well recognized.  However,
the mechanism of the increased incidence of autoimmune diseases in women is not
clear.  Prolactin and androgen levels appear to modulate the lacrimal secretary
cell response in Sjogren's syndrome thus providing an explanation for its gender
bias.  An interesting exception to the gender preference in autoimmune disease
is type 1 diabetes, which has an equal prevalence in males and females. 
Interestingly, however, there is a higher incidence of type 1 diabetes in
offspring when there is paternal, rather than maternal, diabetes.  There is also
the possibility that environmental agents that disrupt the endocrine system, for
example endocrine disrupting chemicals, play a role in autoimmune diseases
although the data are mostly hypothetical at this time.

Most autoimmune diseases also have a genetic component, which may play a role in
the development of pathologic autoimmune responses to environmental agents and
microorganisms.  For example, the cross reactivity of T-cell clones to Coxsackie
protein and GAD65 was only evident in mice with a diabetes susceptible MHC
background.  Equally, the maintenance of HLA-B27 transgenic mice in germ-free
conditions prevents the development of the inflammatory disease.  However, the
NOD mouse develops diabetes at an increased frequency when kept in a "clean"
facility.

Various mechanisms by which infectious agents and environmental agents could
induce autoimmune diseases have been suggested.  The pathogen or environmental
toxicant, chemical or metal, may directly generate an immune response by its
continued presence.  Alternately, the chemical or organism may induce an immune
response, possibly by revealing self antigens that are normally sequestered from
the immune system, and this autoreactive response then becomes self-sustaining. 
This has been shown to occur by molecular mimicry in a mouse model of autoimmune
herpes keratitis.  Whereas in an animal model of type 1 diabetes, by-stander
activation has been implicated.  A role for superantigens, which can be of viral
or bacterial origin, has also been postulated.

Recently NIEHS, NIAID, NIDDK, NIAMS, and NIDR cosponsored two meetings, which
brought together microbiologists, virologists, toxicologists, immunologists and
developmental biologists.  These groups highlighted opportunities for further
research in this area, in particular the effect of genetic factors on the ability
of environmental and infectious agents to initiate, perpetuate, or prevent
autoimmune disease.  They concluded that in most cases a definitive role for
environmental agents, chemical, physical or infectious, in the initiation or
exacerbation of autoimmune diseases is not strong and mechanism are not well
developed and that hypotheses generating pilot/feasibility studies are needed to
move the field forward.

Investigation of the role of environmental agents and pathogens in the
development and regulation of the immune response in autoimmune diseases may lead
not only to understanding of the pathogenesis of these diseases, but also to new
preventive or therapeutic strategies for these diseases.

Research Objectives and Scope

This RFA is designed to support innovative basic, epidemiological, and
preclinical research to understand the role of and mechanisms by which
environmental and infectious agents influence the development and/or the
exacerbation of autoimmune diseases and to understand the role of genes and
hormones in modulating the immune response to environmental and infectious
agents. Relevant topics of research include, but are not limited to, the
following:

o  Identification and characterization of environmental exposures (chemical,
physical or infectious), singly or in combination, that initiate autoimmune
diseases or that exacerbate existing autoimmune diseases.

o  Identification and characterization of periods of exposure to specific
environmental and infectious agents such as during development, perinatal,
prepubertal, adult and aged and sensitivity to the development of autoimmune
disease.

o  Exploration of the possible role of environmental endocrine disrupting
chemicals on the development of autoimmune disease, including interaction with
genes and the hormonal environment.

o  Identification of mechanisms by which environmental agents and pathogens
initiate, potentiate, or perpetuate an autoimmune response.

o  Characterization of molecular, cellular, immunologic, and biological
mechanisms of a host autoimmune associated response to environmental chemicals,
such as solvents, pesticides and metals, and pathogens or pathogen products.

o  Exploitation of the known animal models of microbially- and chemically-induced
autoimmune disease and of the known animal models of autoimmunity for information
on the role of environmental and infectious agents in their pathogenesis.

o  Examination of whether persistence of the pathogen or environmental agent in
the host is necessary to cause disease, or if the agent can  initiate a cascade
of irreversible or reversible immunologic consequences.  What factors determine
the mechanism: the host, the inciting agent, or both?

o  Development of hypothesis-driven investigations to establish the role of
environmental and infectious agents in the etiology of various human autoimmune
diseases and to determine the fraction of cases attributable to environmental or
infectious agents.

The above examples of research approaches are not meant to be all-inclusive or
restrictive.  Investigators are encouraged to develop their own innovative
approaches to achieve the goals of this RFA.  Research in response to this RFA
must have relevance to human autoimmune disease, or idiopathic diseases where
autoimmunity may play a role, however, animal models, in vitro systems, or
epidemiologic studies (pilot or add-on) are appropriate.  A multidisciplinary
approach is encouraged as the areas of interest cross disciplines of immunology,
genetics, infectious diseases and environmental health sciences.

For the purposes of this solicitation, environmental agents include chemical
agents found in the environment, dietary agents, infectious agents, and physical
agents or combinations of the above.  Pharmaceuticals are not part of this RFA.
Applications examining the role of drugs in autoimmune disease will not be
accepted as part of this RFA.  In addition, applications which do not address the
role of environmental or infectious agents in autoimmune disease will not be
accepted in response to this RFA.

SPECIAL REQUIREMENTS

Applicants should include funds for a two-day grantee meeting at the NIEHS in
Research Triangle Park, North Carolina.

INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS

It is the policy of the NIH that women and members of minority groups and their
subpopulations must be included in all NIH supported biomedical and behavioral
research projects involving human subjects, unless a clear and compelling
rationale and justification is provided that inclusion is inappropriate with
respect to the health of the subjects or the purpose of the research. This policy
results from the NIH Revitalization Act of 1993 (Section 492B of Public Law
103-43.

All investigators proposing research involving human subjects should read the
"NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical
Research," which was published in the Federal Register of March 28, 1994 (FR 59
14508-14513) and in the NIH Guide for Grants and Contracts, Vol. 23, No. 11,
March 18, 1994, available on the web at:
https://grants.nih.gov/grants/guide/notice-files/not94-100.html.

INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS

It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by the
NIH, unless there are scientific and ethical reasons not to include them. This
policy applies to all initial (Type 1) applications submitted for receipt dates
after October 1, 1998.

All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the Inclusion of Children as Participants in
Research Involving Human Subjects that was published in the NIH Guide for Grants
and Contracts, March 6, 1998, and is available at the following URL address:
https://grants.nih.gov/grants/guide/notice-files/not98-024.html

Investigators also may obtain copies of these policies from the program staff
listed under INQUIRIES. Program staff may also provide additional relevant
information concerning the policy.

LETTER OF INTENT

Prospective applicants are asked to submit a letter of intent that includes a
descriptive title of the proposed research, the name, address, and telephone
number of the Principal Investigator, the identities of other key personnel and
participating institutions, and the number and title of the RFA in response to
which the application may be submitted. Although a letter of intent is not
required, is not binding, and does not enter into the review of a subsequent
application, the information that it contains allows the program staff of the
participating ICs to estimate the potential review workload and avoid conflict
of interest in the review.

The letter of intent is to be sent to Dr. Ethel Jackson, at the address listed
under INQUIRIES, by the letter of intent receipt date listed in the heading of
this RFA.

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 4/98) is to be used in applying
for these grants.  These forms are available at most institutional offices of
sponsored research and from the Division of Extramural Outreach and Information
Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910,
Bethesda, MD 20892-7910, telephone 301/710-0267, email:  GrantsInfo@nih.gov. 
They may also be downloaded from the Internet at
https://grants.nih.gov/grants/forms.htm

In preparing Modular Grant Applications, standard instructions for specific award
mechanisms should be followed: (PHS 398 and R21), with these specific
modifications reflecting modular budget and just-in-time concepts:

o  Face Page - Items 7a and 7b should be completed, indicating Direct Costs (in
$25,000 increments up to a maximum of $100,000) and Total Costs [Modular Total
Direct plus Facilities and Administrative (F&A) costs] for the initial budget
period.  Items 8a and 8b should be completed indicating the Direct and Total
Costs for the entire proposed period of support.

o  Detailed Budget for the Initial Budget Period - Do not complete Form Page 4
of the PHS 398.  It is not required and will not be accepted with the
application.

o  Budget for the Entire Proposed Period of Support - Do not complete the
categorical budget table on Form Page 5 of the PHS 398.  It is not required and
will not be accepted with the application.

o  Narrative Budget Justification - Use a Modular Grant Budget Narrative page.
(See https://grants.nih.gov/grants/funding/modular/modular.htm for sample pages.) At
the top of the page, enter the total direct costs requested for each year.

o  Under Personnel, List key project personnel, including their names, percent
of effort, and roles on the project. No individual salary information should be
provided.

For Consortium/Contractual costs, provide an estimate of total costs (direct plus
facilities and administrative) for each year, each rounded to the nearest $1,000.
List the individuals/organizations with whom consortium or contractual
arrangements have been made, the percent effort of key personnel, and the role
on the project.  Indicate whether the collaborating institution is foreign or
domestic.  The total cost for a consortium/contractual arrangement is included
in the overall requested modular direct cost amount.

Provide an additional narrative budget justification for any variation in the
number of modules requested.

o  Biographical Sketch - The Biographical Sketch provides information used by
reviewers in the assessment of each individual's qualifications for a specific
role in the proposed project, as well as to evaluate the overall qualifications
of the research team.  A biographical sketch is required for all key personnel,
following the instructions below. No more than three pages may be used for each
person.  A sample biographical sketch may be viewed at:
https://grants.nih.gov/grants/funding/modular/modular.htm

- Complete the educational block at the top of the form page;
- List current position(s) and then previous positions;
- List selected peer-reviewed publications, with full citations;
- Provide information, including overall goals and responsibilities, on research
projects ongoing or completed during the last three years.

o  Other Support - Do not submit the 'other support' pages. Selected other
support relevant to the proposed research may be included in the Biographical
Sketch as indicated above.  Complete other support information will be requested
by the staff of NIEHS or collaborating Institutes if there is a possibility for
an award.

o  Checklist - This page should be completed and submitted with the application.

o  Page Limitation - In keeping with the pilot/feasibility nature of the
requested studies the application (aims, background and significance, preliminary
data and experimental design and methods) is limited to 20 pages. Tables and
figures are included in the 20-page limitation.

o  Appendix - An appendix or additional supporting materials will not be accepted
with the exception of originals of photos used in the application.

The applicant should provide the name and phone number of the individual to
contact concerning fiscal and administrative issues if additional information is
necessary following the initial review.

Comments and inquiries concerning this notice are encouraged.  Nevertheless, the
instructions and procedures described in this notice must be observed.

Additional information, including sample budget narratives and biographical
sketch, may be found at this site:
https://grants.nih.gov/grants/funding/modular/modular.htm.

The RFA label available in the PHS 398 (rev. 4/98) application form must be
affixed to the bottom of the face page of the application.  Failure to use this
label could result in delayed processing of the application such that it may not
reach the review committee in time for review. In addition, the RFA title and
number must be typed on line 2 of the face page of the application form and the
YES box must be marked.

Submit a signed, typewritten original of the application, including the
Checklist, and three signed photocopies, in one package to:

CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710
BETHESDA, MD 20892-7710
BETHESDA, MD 20817 (for express/courier service)

At the time of submission, two additional copies of the application must be sent
to:

Ethel Jackson, D.D.S.
Division of Extramural Research and Training
P.O. Box 12233, MD EC-24
111 T. W. Alexander Drive, East Campus, Rm. 3413  (Courier Service Only) Research
Triangle Park, NC  27709
Telephone:  (919) 541-7846
FAX:  (919) 541-2503
Email:  jackson4@niehs.nih.gov

Applications must be received by the application receipt date listed in the
heading of this RFA.  If an application is received after that date, it will be
returned to the applicant without review.

The Center for Scientific Review (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application.  The CSR
will not accept any application that is essentially the same as one already
reviewed.  This does not preclude the submission of substantial revisions of
applications already reviewed, but such applications must include an introduction
addressing the previous critique.

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed for completeness by the CSR and
responsiveness by the NIH. Incomplete and/or non-responsive applications will be
returned to the applicant without further consideration.

An appropriate peer review group convened by the NIEHS in accordance with the
review criteria stated below will evaluate applications that are complete and
responsive to the RFA for scientific and technical merit. As part of the initial
merit review, a process may be used by the initial review group in which
applications receive a written critique and undergo a process in which only those
applications deemed to have the highest scientific merit, generally the top half
of the applications under review, will be discussed and assigned a priority
score. The scored applications will receive a second level review by the
Institutes National Advisory Council if the direct cost recommended exceeds
$50,000.

REVIEW CRITERIA

The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In the
written comments reviewers will be asked to discuss the following aspects of the
application in order to judge the likelihood that the proposed research will have
a substantial impact on the pursuit of these goals. Each of these criteria will
be addressed and considered in assigning the overall score, weighting them as
appropriate for each application. Note that the application does not need to be
strong in all categories to be judged likely to have major scientific impact and
thus deserve a high priority score. For example, an investigator may propose to
carry out important work that by its nature is not innovative but is essential
to move a field forward.

(1) Significance: Does this study address an important problem in an area covered
by the RFA. If the aims of the application are achieved, how will scientific
knowledge concerning the role of environmental agents, gender, or genetics in the
initiation or exacerbation of autoimmune diseases be advanced?  What will be the
effect of these studies on the concepts or methods that drive this field?

(2) Approach: Are the conceptual framework, design, methods, and analyses
adequately developed, well integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics? In the context of the R21 mechanism, a strong rationale and
conceptual framework are normally sufficient for establishing the feasibility of
the project, in lieu of preliminary data.

(3) Innovation: Does the project employ novel concepts, approaches or methods?
Are the aims original and innovative? Does the project challenge existing
paradigms or develop new methodologies or technologies?  If the project is not
innovative but is essential to move the field forward, the applicant should
mention and discuss this aspect in the proposal.

(4) Investigator: Is the investigator appropriately trained and well suited to
carry out this work? Is the work proposed appropriate to the experience level of
the principal investigator and other researchers (if any)?

(5) Environment: Does the scientific environment in which the work will be done
contribute to the probability of success? Do the proposed experiments take
advantage of unique features of this scientific environment or employ useful
collaborative arrangements? Is there evidence of institutional support?

In addition to the above criteria, in accordance with NIH policy, all
applications will also be reviewed with respect to the following:

The adequacy of plans to include both genders, minorities and their subgroups,
and children as appropriate for the scientific goals of the research. Plans for
the recruitment and retention of subjects will also be evaluated.

The initial review group will also examine the provisions for the protection of
human subjects and the safety of the research environment.

SCHEDULE

Letter of Intent Receipt Date:    March 12, 1999
Application Receipt Date:         May 7, 1999
Peer Review Date:                 June 1999
Council Review:                   September 1999
Earliest Anticipated Start Date:  September 1999

AWARD CRITERIA

Award criteria that will be used to make award decisions include:

o  scientific merit (as determined by peer review)
o  programmatic priorities
o  availability of funds.

INQUIRIES

Inquiries concerning this RFA are encouraged. The opportunity to clarify any
issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues of this RFA to:

Jerrold  J. Heindel, Ph.D.
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233, MD EC-23
111 T. W. Alexander Drive, East Campus, Rm. 3413  (Courier Service Only)
Research Triangle Park, NC 27709
Telephone: (919) 541-0781
FAX: (919) 541-5064
Email: Heindelj@niehs.nih.gov

Elaine Collier, M.D.
Division of Allergy, Immunology, and Infectious Diseases
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 4A20
Bethesda, MD  20892-7640
Telephone:  (301) 496-7104
FAX:  (301) 402-2571
Email: ec5x@nih.gov

Barbara Linder, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases
45 Center Drive, MSC 6600
Bethesda, MD 20892-6600
Telephone:  (301) 594-0021
FAX:  (301) 480-3503
Email: Linderb@extra.niddk.nih.gov

Susana Serrate-Sztein,  M.D.
Arthritis Program Director
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Natcher Building, Room 5AS-25E
Bethesda, MD 20892-6500
Telephone: (301) 594-5032
FAX: (301) 480-4543
Email: ss86e@nih.gov

Karen Winer M.D.
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 4B11
Rockville, MD  20892
Telephone: (301) 435-6877
FAX: (301) 480-9791
Email: winerk@mail.nih.gov

A. Julianna Gulya, M.D.
Clinical Trials Branch
National Institute of Deafness and Other Communication Disorders
6120 Executive Boulevard, Room 400D-7
Rockville, MD  20892
Telephone: (301) 435-4085
FAX: (301) 402-6251
Email: julie_gulya@nih.gov

Ellen Liberman, Ph.D.
National Eye Institute
6210 Executive Boulevard, Suite 350, MSC 7164
Bethesda, MD 20892-7164
Telephone: (301) 496-0484
FAX: (301) 402-0528
Email: ellenliberman@nei.nih.gov

Robert Musson, Ph.D.
National Heart, Lung and Blood Institute
6401 Rockledge Drive, Room 10108
Bethesda, MD  20892-7952
Telephone:  (301) 435-0222
FAX:  (301) 480-3557
Email:  mussonr@gwgate.nhlbi.nih.gov

A.P. Kerza-Dwiatecki, Ph.D.
National Institute of Neurological Disorders and Stroke
7550 Wisconsin Avenue, Room 504
Bethesda, MD 20892
Telephone: (301) 496-1431
FAX: (301) 402-2060
Email: ak45w@nih.gov

Dianne Rausch, Ph.D.
National Institute of Mental Health
6100 Executive Boulevard, Room 6209  MSC-9619
Bethesda, MD  20892-6100
Telephone:  (301) 443-6100
FAX:  (301) 443-9719
Email:  drausch@mail.nih.gov

Kenneth A. Gruber, Ph.D.
Chronic and Disabling Diseases Program
National Institute of Dental and Craniofacial Research
Building 45, Room 4AN-18C
Bethesda, MD 20892
Telephone: (301) 594-4836
FAX: (301) 480-8318
Email: kenneth_gruber@nih.gov

Vivian Pinn, Ph.D.
Office of Research on Women's Health
National Institutes of Health
Building 1, Room 201
Bethesda, MD  20892
Telephone:  (301) 402-1770
FAX:  (301) 402-1798
Email:  pinnv@od.nih.gov

Direct inquiries regarding fiscal matters to:

Mr. David Mineo
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O Box 12233 (EC-22)
Research Triangle Park NC, 27709
Telephone: (919) 541-1373
FAX: (919) 541-2860
Email: mineo@niehs.nih.gov

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance No.
93.113 - Biological Responses to Environmental Health Hazards, and No. 93.856
'Microbiological and Infectious Disease Research, and No, 93.855 ' Immunology,
Allergy, and Transplantation Research. Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by
Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies
and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject
to the intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.

The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and promote the non-use of all tobacco products. In addition, Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care, or early childhood development
services are provided to children. This is consistent with the PHS mission to
protect and advance the physical and mental health of the American people.

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)